Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia. Issue 1 (23rd October 2019)

• Record Type: Journal Article
• Authors: Zeijlemaker, Wendelien; Kelder, Angele; Cloos, Jacqueline; Schuurhuis, Gerrit Jan
• Editors: Robinson, J. Paul; Darzynkiewicz, Zbigniew; Dobrucki, Jurek; Hyun, William C.; Nolan, John P.; Orfao, Alberto; Rabinovitch, Peter S.
• Is Part Of: Current protocols in cytometry. Volume 91:Issue 1(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-10-23
• Subjects: acute myeloid leukemia (AML) -- leukemia associated immunophenotypes (LAIPs) -- leukemic stem cells (LSCs) -- measurable residual disease (MRD) -- multiparameter flow cytometry (MFC); Cytology -- Laboratory manuals; Flow cytometry -- Laboratory manuals; Cell separation -- Laboratory manuals; Molecular biology -- Laboratory manuals; Flow Cytometry -- methods; Image Cytometry -- methods; Cell Separation -- methods; Cytological Techniques; Molecular Biology -- methods; Cell separation; Cytology; Flow cytometry; Molecular biology; Laboratory Manuals; Laboratory manuals; 571.6
• DOI: 10.1002/cpcy.66
• Languages: English
• ISSNs: 1934-9297

Abstract

Abstract: Half of the patients with acute myeloid leukemia (AML), who achieve complete remission after chemotherapy treatment, will ultimately experience a relapse. Measurable residual disease (MRD) is an important post‐treatment risk factor in AML, because it gives additional information about the depth of the remission. Within MRD, the small population of leukemic stem cells (LSCs) is thought to be at the base of the actual relapse. In this protocol, the flow cytometric detection of MRD and LSCs herein is outlined. We give a detailed overview of the sampling procedures for optimal multiparameter flow cytometry assessment of both MRD and LSC, using leukemia associated immunophenotypes (LAIPs) and LSC markers. Moreover, an overview of the gating strategies to detect LAIPs and LSC markers is provided. This protocol serves as guidance for flow cytometric detection of measurable residual (stem cell) disease necessary for proper therapeutic decision making in AML patients. © 2019 The Authors. Basic Protocol 1 : Immunophenotypic LAIP detection for measurable residual disease monitoring Basic Protocol 2 : Immunophenotypic detection of CD34+CD38− leukemic stem cells